Vivek Agrawal CFA
Stock Analyst at Citi
(0.46)
# 4,367
Out of 5,014 analysts
22
Total ratings
44.4%
Success rate
-13%
Average return
Main Sectors:
Stocks Rated by Vivek Agrawal CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSE: DRREDDY Dr. Reddy's Laboratories Limited | Upgraded: Buy | ₹990.00 → ₹1,450 | ₹1,233 | +17.60% | 2 | Sep 28, 2026 | |
| NSE: CIPLA Cipla Limited | Reiterated: Buy | n/a | $1,346.00 | - | 2 | Jul 24, 2026 | |
| NSE: SUNPHARMA Sun Pharmaceutical Industries Limited | Reiterated: Buy | ₹2,180 | ₹1,817 | n/a | 2 | Sep 30, 2025 | |
| NSE: MAXHEALTH Max Healthcare Institute Limited | Reiterated: Buy | ₹1,460 | ₹929.80 | n/a | 1 | Aug 11, 2025 | |
| NSE: AUROPHARMA Aurobindo Pharma Limited | Reiterated: Sell | ₹1,100 → ₹1,010 | ₹1,672 | n/a | 3 | Aug 6, 2025 | |
| NSE: LAURUSLABS Laurus Labs Limited | Reiterated: Sell | ₹500.00 → ₹590.00 | ₹1,980 | n/a | 2 | Jul 28, 2025 | |
| NSE: GLAND Gland Pharma Limited | Reiterated: Sell | ₹1,680 | ₹2,899 | n/a | 1 | Jul 22, 2025 | |
| NSE: APOLLOHOSP Apollo Hospitals Enterprise Limited | Reiterated: Buy | ₹8,260 | ₹8,166 | n/a | 1 | Jun 30, 2025 | |
| NSE: DIVISLAB Divi's Laboratories Limited | Reiterated: Buy | ₹7,050 → ₹7,750 | ₹9,292 | n/a | 2 | May 19, 2025 | |
| NSE: LALPATHLAB Dr. Lal PathLabs Limited | Reiterated: Sell | ₹1,350 | ₹1,987 | n/a | 1 | Apr 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ₹700.00 | ₹818.50 | n/a | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | ₹2,260 | ₹2,030 | n/a | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | ₹2,330 → ₹1,880 | ₹1,374 | n/a | 2 | Feb 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ₹430.00 | ₹370.30 | n/a | 1 | Feb 3, 2025 |
Dr. Reddy's Laboratories Limited
Sep 28, 2026
Upgraded: Buy
Price Target: ₹990.00 → ₹1,450
Current: ₹1,233
Upside: +17.60%
Cipla Limited
Jul 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $1,346.00
Upside: -
Sun Pharmaceutical Industries Limited
Sep 30, 2025
Reiterated: Buy
Price Target: ₹2,180
Current: ₹1,817
Upside: n/a
Max Healthcare Institute Limited
Aug 11, 2025
Reiterated: Buy
Price Target: ₹1,460
Current: ₹929.80
Upside: n/a
Aurobindo Pharma Limited
Aug 6, 2025
Reiterated: Sell
Price Target: ₹1,100 → ₹1,010
Current: ₹1,672
Upside: n/a
Laurus Labs Limited
Jul 28, 2025
Reiterated: Sell
Price Target: ₹500.00 → ₹590.00
Current: ₹1,980
Upside: n/a
Gland Pharma Limited
Jul 22, 2025
Reiterated: Sell
Price Target: ₹1,680
Current: ₹2,899
Upside: n/a
Apollo Hospitals Enterprise Limited
Jun 30, 2025
Reiterated: Buy
Price Target: ₹8,260
Current: ₹8,166
Upside: n/a
Divi's Laboratories Limited
May 19, 2025
Reiterated: Buy
Price Target: ₹7,050 → ₹7,750
Current: ₹9,292
Upside: n/a
Dr. Lal PathLabs Limited
Apr 27, 2025
Reiterated: Sell
Price Target: ₹1,350
Current: ₹1,987
Upside: n/a
Mar 12, 2025
Initiated Coverage: Buy
Price Target: ₹700.00
Current: ₹818.50
Upside: n/a
Mar 5, 2025
Upgraded: Buy
Price Target: ₹2,260
Current: ₹2,030
Upside: n/a
Feb 16, 2025
Reiterated: Hold
Price Target: ₹2,330 → ₹1,880
Current: ₹1,374
Upside: n/a
Feb 3, 2025
Reiterated: Buy
Price Target: ₹430.00
Current: ₹370.30
Upside: n/a